Early detection is the single most powerful weapon against cancer. This panel includes prostate-specific antigen (PSA) and related markers to support early identification of prostate health concerns in men.
Cancer is fundamentally a disease of accumulated genetic mutations that allow cells to divide uncontrollably, evade immune surveillance, and invade surrounding tissues. The probability of successful treatment correlates inversely with the stage at diagnosis — cancers detected at stage I carry 5-year survival rates exceeding 90% for most types, while stage IV cancers often have survival rates below 20%. This biological reality makes early detection — ideally before symptoms develop — the most powerful intervention available.
Blood-based cancer screening occupies the intersection of preventive medicine and oncology. Tumour markers like PSA quantify proteins shed by abnormal cells into circulation, providing a non-invasive window into glandular health. While no single blood test is perfectly sensitive or specific for any cancer, tumour markers in the context of appropriate clinical history, physical examination, and imaging provide actionable early detection opportunities — particularly for prostate cancer, where PSA surveillance has meaningfully reduced prostate cancer mortality.
Cancer Screening health does not exist in isolation — it is deeply intertwined with every major system.
The immune system continuously surveils for and eliminates pre-cancerous and cancerous cells through a process called immunosurveillance. Natural killer (NK) cells, cytotoxic T lymphocytes, and macrophages identify and destroy cells displaying abnormal surface antigens. Cancer cells evade this surveillance by downregulating MHC-I presentation, overexpressing PD-L1 (a 'don't kill me' signal), and creating an immunosuppressive tumour microenvironment. Chronic inflammation, through sustained oxidative DNA damage and suppression of NK cell activity, both increases mutation rates and impairs immunosurveillance — explaining why chronic inflammatory conditions increase cancer risk.
Oestrogen drives proliferation of hormone-receptor-positive breast cancer cells; testosterone fuels androgen-sensitive prostate cancer. This is why hormonal influences — endogenous and exogenous — are central to breast and prostate cancer risk and treatment. Elevated IGF-1 (insulin-like growth factor 1) promotes cell proliferation in multiple cancer types, linking metabolic health to cancer risk. Insulin itself acts as a growth factor — chronically elevated insulin from insulin resistance may promote colon and endometrial cancer cell growth via insulin and IGF-1 receptors.
Liver cirrhosis from any cause — alcohol, hepatitis B/C, NAFLD — dramatically elevates risk of hepatocellular carcinoma (HCC). AFP (alpha-fetoprotein) is elevated in 60–70% of HCC cases and serves as both a screening marker (biannually in cirrhotic patients via ultrasound) and treatment response monitor. Elevated AFP outside the context of liver disease warrants investigation for testicular germ cell tumours. Chronic HBV and HCV infection are the largest preventable causes of liver cancer globally, making viral hepatitis screening a critical cancer prevention tool.
Chronic inflammation is now established as one of the "hallmarks of cancer" — persistent inflammatory signalling promotes tumour initiation, progression, and metastasis. H. pylori infection drives gastric cancer through decades of gastric mucosal inflammation. Inflammatory bowel disease increases colorectal cancer risk 2–3-fold. Elevated hs-CRP is associated with increased incidence of colon, lung, and pancreatic cancer in large cohort studies. Anti-inflammatory interventions including aspirin and NSAIDs reduce colorectal adenoma and cancer risk in randomised trials.
Clinical Note
Tumour markers must always be interpreted in clinical context — no marker is specific enough to diagnose cancer in isolation. PSA can be elevated by benign prostate enlargement, prostatitis, and recent sexual activity. AFP can be elevated in liver inflammation, pregnancy, and benign ovarian tumours. A concerning tumour marker should prompt specialist evaluation, imaging, and biopsy where indicated — not immediate alarm based on the number alone.
Prostate-specific antigen (PSA) is a protein produced exclusively by prostate cells. Small amounts are normally present in blood; elevated levels can indicate prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis (prostate infection/inflammation). A PSA above 4.0 ng/mL is the traditional threshold for further evaluation, but risk is elevated even at lower levels — particularly in younger men. PSA velocity (how fast PSA is rising over time) and PSA density (PSA relative to prostate size) provide more informative context than a single reading.
The American Cancer Society recommends discussing PSA screening at age 50 for average-risk men. Men at high risk — including African American men and those with a first-degree relative diagnosed with prostate cancer before age 65 — should begin the conversation at age 40–45. The US Preventive Services Task Force recommends shared decision-making for men aged 55–69, noting that benefits and harms of screening must be weighed individually. Annual PSA testing is appropriate once baseline is established.
PSA circulates in two forms: bound to proteins and free (unbound). In prostate cancer, a higher proportion of PSA is protein-bound, reducing the free-to-total ratio. When total PSA is in the 4–10 ng/mL "grey zone," the free PSA ratio helps determine whether a biopsy is warranted. A free PSA ratio below 10% strongly suggests prostate cancer. A ratio above 25% is more consistent with benign prostate enlargement. This ratio reduces unnecessary biopsies in men with moderately elevated PSA.
Yes. Benign prostatic hyperplasia (BPH), an age-related non-cancerous enlargement of the prostate, commonly elevates PSA proportionally to prostate size. Prostatitis (bacterial or inflammatory) can dramatically spike PSA, sometimes to 50+ ng/mL during acute episodes. Ejaculation within 48 hours before testing, vigorous cycling, and prostate biopsies all transiently raise PSA. Finasteride and dutasteride (BPH medications) reduce PSA by approximately 50%, so reported levels must be doubled for accurate interpretation in men on these drugs.
While PSA is the primary blood-based cancer screening marker in routine preventive panels, other tumour markers serve specific contexts. CA-125 is used in women with risk factors for ovarian cancer. CEA (carcinoembryonic antigen) monitors colorectal cancer treatment response. AFP (alpha-fetoprotein) screens for hepatocellular carcinoma in people with liver cirrhosis. These markers are generally not used for population-level primary screening due to insufficient specificity — they generate false positives in benign conditions. Multi-cancer early detection (MCED) blood tests analysing cell-free DNA represent the next generation of cancer screening.
Join thousands who have discovered their health optimization opportunities through comprehensive cancer screening testing.